CHURCH & DWIGHT CO INC /DE/ (CHD) stock intrinsic value fair value estimate & owner earnings analysis

Church & Dwight sells everyday household and personal-care products under a portfolio of brands. Seven "power brands" - Arm & Hammer, OxiClean, Batiste, Waterpik, TheraBreath, Hero and Touchland - generate roughly 70% of sales and profit, with Trojan, First Response, Nair and others behind them. Most sales are in the United States and Walmart alone is about 23% of sales; the top four retailers are about 44%. Sales have grown every year for ten years, from about $3.5 billion in 2016 to $6.2 billion in 2025, and demand for these products is not discretionary. How we measured earnings. We use the cash the business generates from operations, remove the swings from working capital (receivables, inventory, payables), subtract stock compensation as a real cost, and subtract the capital spending needed to keep the plants and systems running. On that basis owner earnings per share were about $2.44 in 2017, $3.26 in 2020, $3.53 in 2021, dipped to $3.03 in 2022 when commodity and freight inflation squeezed margins, then recovered to $3.09, $3.77 and $4.21 in 2023 to 2025. The large non-cash write-downs in 2022 (Flawless, $411 million) and 2024 (vitamin trade name and assets, $357 million) and the $58.5 million loss on selling the vitamin business are added back, because the cash was spent in the original acquisitions; the cost of those misses is reflected instead in how cautiously we treat future growth and in the bear case. We value the business before its lenders and then subtract what it owes. For that purpose we add back the roughly $95 million a year of cash interest the company pays, giving business cash flow of about $876 million in 2023, $1,025 million in 2024 and $1,122 million in 2025. As our starting level we use the middle year of 2023 to 2025, about $1,025 million, the period after the company's biggest recent acquisitions were absorbed and after the 2022 cost shock. We left 2022 out of the starting level because it was distorted by that inflation spike, and the bear case below carries a repeat of that kind of episode explicitly. That starting level is below 2025's actual $1,122 million, and the first half of 2026 (operating cash flow of $462 million against $417 million a year earlier; net sales up 0.9%) does not argue for lowering it. What changed in the business since our last review. In 2025 the company bought Touchland (hand sanitizer, about $115 million of 2024 sales; $656 million paid at closing and a further $159 million earn-out paid in the first half of 2026 because sales targets were met), exited Flawless, Spinbrush and Waterpik showerheads (about $118 million of sales), and sold the VitaFusion and L'il Critters vitamin brands on December 31, 2025, a business that had required a $357 million write-down. The share count has also fallen from 244 million to 238 million diluted shares in 2026. On the other hand the Waterpik brand is losing distribution as consumers move to value brands, and the company says the Waterpik trade name's value now exceeds its carrying value by only 17%; some customers launched private-label competitors in 2025. Our previous estimates were built on a different basis and are not comparable with these figures. Debt. The company owes $2,225 million of senior notes plus $50 million of commercial paper: $425 million at 3.15% due August 2027, $400 million at 2.3% due December 2031, $500 million at 5.6% due 2032, $400 million at 3.95% due 2047 and $500 million at 5.0% due 2052. Because most of this is fixed well below what new borrowing costs, we reduce the debt figure by about $248 million for the value of those cheap coupons. Cash was $255 million at June 30, 2026. Net of both, the company owes about $1.77 billion, or about $7.44 per share. Business cash flow is more than eight times annual interest even in our bear case, and the only near-term maturity ($425 million in 2027) is small relative to the cash the business produces. Base case (about $68 per share). Business worth about $75.40 per share, less $7.44 owed, leaves about $68. Business cash flow starts at about $1,025 million and grows 2% a year for ten years to about $1.25 billion, then stays level for a further thirty years and is then valued at zero. Last year business cash flow grew about 9%; we assume less because only part of that came from sources we can count on, and we do not assume any rebound. What we credited: price and volume growth no faster than the company's ten-year record of annual sales growth, the sustained productivity savings it reports (about 1.6 percentage points of gross margin a year, which have offset cost inflation), and the level of the legacy brands that have lasted for a century or more (Arm & Hammer dates to 1867). What we left out: further acquisitions, which require spending and have a mixed record here; market expansion; share gains; margin expansion; and international growth of the newer brands. Bear case (about $36 per share). Business worth about $43.00 per share, less $7.44 owed, leaves about $35.60. Starting from the same level, business cash flow falls 10% a year for two years and 5% in the third, to about $789 million, and stays there for 22 more years before ending. The first two steps repeat the 2022 episode, when business cash flow fell about 11% in one year on commodity, freight and promotional pressure, and the third reflects named problems that are already visible: Waterpik distribution losses, tariffs on Chinese-made Waterpik flossers, and retailers (Walmart is 23% of sales, the top four are 44%) expanding private-label products onto the shelf. The 2027 notes are refinanced at a higher rate; the company's cash flow covers interest many times over throughout, so this case does not endanger the company. Further write-offs of acquisitions are the pattern in this business ($411 million Flawless, $357 million vitamins, $58.5 million vitamin sale loss in the last four years), and no new growth from deals is credited. Bull case (about $89 per share). Business worth about $96.10 per share, less $7.44 owed, leaves about $88.60. Business cash flow starts at the 2025 level of about $1,122 million (a level already reached and still supported by first-half 2026 cash flow) and grows 4% a year for ten years, to about $1.66 billion, then stays level for thirty years before ending. This rests on levers the company already controls: Touchland, which exceeded the sales thresholds that triggered the $159 million earn-out; the exit of the underperforming vitamin and hair-removal lines; continued productivity programs; and the growth record of TheraBreath and Hero. What would make this wrong. The base case would be too high if the Waterpik decline spreads to other power brands, if private label takes lasting shelf space at Walmart and the other large retailers, or if tariff and commodity costs rise faster than the productivity savings that have offset them. It would be too low if the 2025 and first-half 2026 improvement in operating cash flow proves a new lasting level rather than a recovery. Margin-of-safety price. We are reasonably sure of the earnings level: it comes from a ten-year record of positive cash flow, products that are bought regardless of the economy, and no year since 2016 in which business cash flow fell by more than about 11%. The worst plausible outcome is a multi-year erosion in which Walmart and other large customers favour private label and input costs stay elevated; the debt is modest and mostly fixed at low rates, so the company would survive that, though earnings would be lower for a long time and acquisitions made over recent years (Waterpik, Flawless, vitamins) could be written down further. If we are wrong about the starting level by 10% and about long-term growth by 2 percentage points, the shares would be worth around $50; if the Waterpik and private-label problems prove larger than in our bear case, below $30 is possible. The price assumes a holding period of about five years. During that period, the company pays a dividend of $1.18 per share (2025, rising each year) and buys back stock. The margin-of-safety price is about $36 per share. That price is about equal to the bear value, while from that price the base case implies roughly 20% a year including dividends over five years; a much higher price would depend on the base case being the likely outcome when a wide range of outcomes is plausible.